Precision Biosciences Inc (DTIL): Revenue
$34.26M
Year ended 2025-12-31
$45.05M
Trailing 12 months to 2026-06-30
+10.9%
3-year compound annual growth
+7.1%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $34.26M | -50.1% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $68.70M | +41.0% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $48.73M | +94.1% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $25.10M | -78.3% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $115.53M | +375.7% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $24.29M | +9.2% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $22.24M | +104.3% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $10.88M | n/a | 2020-03-10, From 2018-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $34.26M | -50.1% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $35.11M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $35.95M | +1.0% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $30.25M | -46.5% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $39.21M | -16.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $39.55M | -31.6% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $40.37M | -49.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $40.52M | +25.4% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $44.64M | -6.1% |
Compare DTIL, XFOR, CCCC, SCLX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗